CHMP’s February 2024 Meeting: New Drug Recommendations

By Staff Writer

February 24, 2024

Introduction:

The Committee for Medicinal Products for Human Use (CHMP) held its February 2024 meeting with numerous noteworthy outcomes. CHMP assessments are based on extensive scientific data analysis. They assess innovative drugs quality, safety, efficacy, and risk-benefit ratio. Internal peer-review ensures committee opinions are accurate and valid. In this article we highlight the key takeaways and their outcomes.

Ten New Medicines for Approval

The CHMP meeting saw the recommendation of ten new innovative medicines for approval. Two of these were vaccines aimed at active immunisation against the H5N1 subtype of influenza A virus, more commonly known as avian influenza or bird flu. The vaccines, Celldemic and Incellipan, are designed for immunisation during outbreaks of influenza from animals, including potential pandemics.

Innovations in Disease Treatment

Other significant recommendations included Filspari for the treatment of primary immunoglobulin A nephropathy, a disease where the kidneys gradually cease functioning, and Qalsody, a new therapy for treating adult patients with amyotrophic lateral sclerosis (ALS), a rare and often fatal disease, causing muscle weakness and leading to paralysis.

Advancements in Cancer and Blood Treatment

The meeting also saw positive opinions in the oncology and haematology landscape, including a recommendation for Tizveni, a treatment for locally advanced or metastatic non-small cell lung cancer, and Zynyz, a treatment for Merkel cell carcinoma, a life-threatening skin cancer with poor outcomes with advanced disease. Furthermore, the CHMP endorsed Voydeya, the first oral treatment for residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria, a rare genetic disorder that causes the immune system to prematurely break down red blood cells. Voydeya was classified as an orphan drug during its development phase.

Biosimilar and Generic Medicines Approved

The CHMP meeting also saw the approval of Pyzchiva, an ustekinumab biosimilar intended for the treatment of plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease. In addition, two generic medicines received a positive opinion from the committee: Apremilast Accord for the use in the treatment of psoriatic arthritis, psoriasis and Behçet’s disease and also Nintedanib Accord for adults with idiopathic pulmonary fibrosis, other chronic fibrosing interstitial lung diseases with a progressive phenotype, and systemic sclerosis associated interstitial lung disease.

Extensions of Therapeutic Indication

The CHMP meeting recommended extensions of indication for six medicines already authorised in the European Union, including Carvykti, Cibinqo, Kalydeco, Keytruda, Reblozyl, and Xromi. The applicants for Nezglyal (also initially an orphan drug) and Syfovre requested the January 2024 committee’s opinions reexamined, and final recommendations will be provided.

Conclusion:

The outcomes of the CHMP February 2024 meeting highlight the importance of a well-defined peer-review committee in the healthcare sector in order to evaluate and recommend new and innovative medicines. By ensuring an evidence-based process the CMHP strives to provide high level recommendations and allows for a thriving healthcare system which provides ample opportunity for innovation.

Reference url

Recent Posts

implantable glucose device
         

T1 Diabetes Care with an Implantable Glucose Device

🚀 Are we on the brink of a diabetes breakthrough?

A newly developed implantable glucose device from MIT could revolutionize diabetes management, providing an autonomous solution to prevent life-threatening hypoglycemic episodes. This innovative device combines continuous glucose monitoring with responsive hormone delivery, potentially transforming patient care by reducing the need for constant oversight.

Curious about how this technology could reshape diabetes outcomes and healthcare economics? Dive into the full article for a closer look!

#SyenzaNews #HealthTech #HealthEconomics #Innovation

federated learning governance
      

Federated Learning Governance in Healthcare: A Framework for Ethical and Effective Implementation

🔍 Have you considered how federated learning governance can revolutionize healthcare data collaboration?

In our latest article, we explore the critical principles of federated learning governance, emphasizing its role in managing decentralized health data while protecting patient privacy and improving research quality. Learn about the actionable strategies healthcare organizations can implement to navigate the unique challenges that come with this innovative approach.

Dive deeper into the world of federated learning in healthcare and unlock its potential for ethical and effective data use!

#SyenzaNews #AIinHealthcare #DigitalHealth

Cecolin 9 HPV vaccine
        

Cecolin 9 HPV Vaccine: A Game Changer for Cervical Cancer Prevention in China

🌍 Did you know that China has just achieved a historic milestone in the fight against cervical cancer?

The approval of the Cecolin 9 HPV vaccine, the first domestically developed 9-valent HPV vaccine, marks a transformative moment for public health, enhancing access and affordability across the nation. This development not only meets global health goals but also reshapes the landscape of cervical cancer prevention in China.

Curious to learn how this advancement is set to impact vaccination efforts and healthcare economics? Dive into the full article for deeper insights!

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.